Cesar Cabello Selected Research

Biomarkers (Surrogate Marker)

1/2020	ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
5/2017	18F-Fluoride PET/CT tumor burden quantification predicts survival in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Cesar Cabello Research Topics

Disease

7	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2017
4	Neoplasms (Cancer) 09/2022 - 05/2017
1	Unilateral Breast Neoplasms 03/2020
1	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/2014

Drug/Important Bio-Agent (IBA)

2	Phenobarbital (Luminal)FDA Link 09/2022 - 04/2021
2	Estrogen ReceptorsIBA 09/2022 - 01/2020
2	Biomarkers (Surrogate Marker)IBA 01/2020 - 05/2017
1	Aromatase InhibitorsIBA 01/2020

Therapy/Procedure

5	Therapeutics 04/2021 - 05/2017
1	Treatment Delay 01/2022
1	Segmental Mastectomy (Lumpectomy) 04/2021
1	Radiotherapy 04/2021
1	Drug Therapy (Chemotherapy) 04/2021
1	Neoadjuvant Therapy 03/2020
1	Adjuvant Chemotherapy 05/2017
1	Colectomy 01/2014